Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 4/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.35 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.34 |
| ▸ | CYP2E1 | P05181 | 4/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 4/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.33 |
| ▸ | CYP2B6 | P20813 | 4/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.33 |
| ▸ | TDO2 | P48775 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.31 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.30 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.30 |
| ▸ | KIF11 | P52732 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21151453 | 0.64 | ALDH1A1 (0.53) | TAAR1NOTUMCYP3A4ALDH1A1CYP1A2 | |
| Biphenyl SCHEMBL21932883 | 0.61 | ALDH1A1 (0.69) | TAAR1DPP4NOTUMLOXL2CYP2E1 | |
| Biphenyl SCHEMBL10333738 | 0.59 | ALDH1A1 (0.64) | TAAR1DPP4NOTUMLOXL2CYP3A4 | |
| Biphenyl SCHEMBL27410798 | 0.58 | TAAR1 (0.84) | TAAR1DPP4LOXL2CYP2E1CYP3A4 | |
| Biphenyl SCHEMBL27882978 | 0.57 | ALDH1A1 (0.60) | TAAR1DPP4NOTUMLOXL2CYP3A4 | |
| Biphenyl SCHEMBL27334830 | 0.57 | ALDH1A1 (0.60) | TAAR1DPP4LOXL2CYP3A4CHRNB2 | |
| Biphenyl SCHEMBL4840882 | 0.57 | ALDH1A1 (0.60) | TAAR1DPP4NOTUMLOXL2CYP3A4 | |
| SCHEMBL22291708 | 0.57 | TAAR1 (1.00) | TAAR1LOXL2CYP3A4CYP2A6CHRNB2 | |
| SCHEMBL22202237 | 0.57 | TAAR1 (1.00) | TAAR1LOXL2CYP3A4CYP2A6CHRNB2 | |
| SCHEMBL6527260 | 0.55 | ALDH1A1 (0.47) | TAAR1NOTUMCYP3A4ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1680420-A4 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS INC (US) | 2008-09-24 | — | — | EP | claimed |
| JP-2007510660-A | — | — | 2007-04-26 | — | — | JP | claimed |
| EP-1680420-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | Cytokinetics, Inc. (US) | 2006-07-19 | — | — | EP | claimed |
| US-20060111374-A1 | Compounds, compositions, and methods | CYTOKINETICS, INC. | 2006-05-25 | — | — | US | claimed |
| US-20050148593-A1 | Treating cell proliferation disorder, anticancer agents | CYTOKINETICS, INC. | 2005-07-07 | — | — | US | claimed |
| WO-2005046588-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2005-05-26 | — | — | WO | claimed |
| US-20040116438-A1 | Compounds, compositions, and methods | CYTOKINETICS, INCORPORATED | 2004-06-17 | — | — | US | claimed |
| EP-1680420-A4 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS INC (US) | 2008-09-24 | — | — | EP | disclosed |
| US-7332498-B2 | Modulation of KSP kinesin activity with heterocyclic-fused pyrimidinone derivatives | CYTOKINETICS, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| EP-1513820-A4 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS INC (US) | 2006-09-13 | — | — | EP | disclosed |
| EP-1680420-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | Cytokinetics, Inc. (US) | 2006-07-19 | — | — | EP | disclosed |
| US-20060111374-A1 | Compounds, compositions, and methods | CYTOKINETICS, INC. | 2006-05-25 | — | — | US | disclosed |
| US-7038048-B2 | 3H-pyridopyrimidin-4-one compounds, compositions, and methods of their use | CYTOKINETICS, INC. (US) | 2006-05-02 | — | — | US | disclosed |
| US-20050148593-A1 | Treating cell proliferation disorder, anticancer agents | CYTOKINETICS, INC. | 2005-07-07 | — | — | US | disclosed |
| WO-2005046588-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2005-05-26 | — | — | WO | disclosed |
| EP-1513820-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | Cytokinetics, Inc. (US) | 2005-03-16 | — | — | EP | disclosed |
| US-20040116438-A1 | Compounds, compositions, and methods | CYTOKINETICS, INCORPORATED | 2004-06-17 | — | — | US | disclosed |
| WO-2003103575-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2003-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148593-A1 | Treating cell proliferation disorder, anticancer agents | MKI67, PCNA, CCNH | TAAR1 4729/4885DPP4 4618/4885NOTUM 3213/4885 |
| US-20060111374-A1 | Compounds, compositions, and methods | ALPP, MKI67, PCNA | TAAR1 4835/4885DPP4 4611/4885NOTUM 1950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.